Novel HER2 TKI Shows Preliminary Activity in Breast Cancer Brain Metastases

Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.

Source: www.cancernetwork.com

Categories: Oncologists1, General Medicine News

Tags: bcsm

Tweets with this article

Cancer Network

Data from the phase 1c portion of the trial included 40 patients—with 37 being evaluated for efficacy—and showed a confirmed ORR of 73.0% (95% CI, 55.88%-86.21%), with a median DOR of 12.6 months (95% CI, 6.70-16.59). #bcsm https://t.co/frJ0HrT7GA

Cardio Onc year in review

JACC: CardioOncology, 2024, Year-in-review, most viewed papers, best of 2024

Oncology Advance January 10, 2025

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

OncLive.com January 10, 2025

Impact of Non-ABL1 Mutations on Outcomes in Chronic Myeloid Leukemia

Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.

Targeted Oncology January 10, 2025

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

OncLive.com January 10, 2025

AUA 2024: Disrupting the Field of Urology

Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.